EBMT 2018 | Reducing hyperhydration in patients undergoing transplantation

Midori Nakagaki

Hyperhydration is typically used along with high-dose melphalan in patients undergoing stem cell transplantation. However, the evidence behind this practice is limited and the dosage administered to patients needs refining. In this interview, Midori Nakagaki, BPharm, MSc, from the Royal Brisbane Hospital, Brisbane, Australia, discusses the findings of her group’s study retrospectively comparing patients’ response with hyperhydration vs. without hyperhydration. Midori emphasizes the advantages in reducing dosage, namely easing the workload for healthcare professionals and minimizing the pressures on patients. This video was recorded at the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting in Lisbon, Portugal.

Share this video  
18th March 2018

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter